|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 6/19/14 Aurinia Pharmaceuticals Inc. 40FR12B/A 6/18/14 86:8.8M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 40FR12B/A Amendment to Registration of Securities of a HTML 62K
Canadian Issuer -- SEA'34 §12(b)
2: EX-99.1 Miscellaneous Exhibit HTML 27K
11: EX-99.10 Miscellaneous Exhibit HTML 26K
12: EX-99.11 Miscellaneous Exhibit HTML 23K
13: EX-99.12 Miscellaneous Exhibit HTML 23K
14: EX-99.13 Miscellaneous Exhibit HTML 22K
15: EX-99.14 Miscellaneous Exhibit HTML 22K
16: EX-99.15 Miscellaneous Exhibit HTML 365K
17: EX-99.16 Miscellaneous Exhibit HTML 308K
18: EX-99.17 Miscellaneous Exhibit HTML 369K
19: EX-99.18 Miscellaneous Exhibit HTML 426K
20: EX-99.19 Miscellaneous Exhibit HTML 414K
3: EX-99.2 Miscellaneous Exhibit HTML 27K
21: EX-99.20 Miscellaneous Exhibit HTML 186K
22: EX-99.21 Miscellaneous Exhibit HTML 236K
23: EX-99.22 Miscellaneous Exhibit HTML 302K
24: EX-99.23 Miscellaneous Exhibit HTML 200K
25: EX-99.24 Miscellaneous Exhibit HTML 210K
26: EX-99.25 Miscellaneous Exhibit HTML 152K
27: EX-99.26 Miscellaneous Exhibit HTML 166K
28: EX-99.27 Miscellaneous Exhibit HTML 193K
29: EX-99.28 Miscellaneous Exhibit HTML 236K
30: EX-99.29 Miscellaneous Exhibit HTML 139K
4: EX-99.3 Miscellaneous Exhibit HTML 25K
31: EX-99.30 Miscellaneous Exhibit HTML 284K
32: EX-99.31 Miscellaneous Exhibit HTML 24K
33: EX-99.32 Miscellaneous Exhibit HTML 26K
34: EX-99.33 Miscellaneous Exhibit HTML 23K
35: EX-99.34 Miscellaneous Exhibit HTML 33K
36: EX-99.35 Miscellaneous Exhibit HTML 30K
37: EX-99.36 Miscellaneous Exhibit HTML 628K
38: EX-99.37 Miscellaneous Exhibit HTML 296K
39: EX-99.38 Miscellaneous Exhibit HTML 27K
40: EX-99.39 Miscellaneous Exhibit HTML 26K
5: EX-99.4 Miscellaneous Exhibit HTML 25K
41: EX-99.40 Miscellaneous Exhibit HTML 283K
42: EX-99.41 Miscellaneous Exhibit HTML 89K
43: EX-99.42 Miscellaneous Exhibit HTML 280K
44: EX-99.43 Miscellaneous Exhibit HTML 25K
45: EX-99.44 Miscellaneous Exhibit HTML 30K
46: EX-99.45 Miscellaneous Exhibit HTML 31K
47: EX-99.46 Miscellaneous Exhibit HTML 32K
48: EX-99.47 Miscellaneous Exhibit HTML 46K
49: EX-99.48 Miscellaneous Exhibit HTML 26K
50: EX-99.49 Miscellaneous Exhibit HTML 30K
6: EX-99.5 Miscellaneous Exhibit HTML 24K
51: EX-99.50 Miscellaneous Exhibit HTML 28K
52: EX-99.51 Miscellaneous Exhibit HTML 54K
53: EX-99.52 Miscellaneous Exhibit HTML 37K
54: EX-99.53 Miscellaneous Exhibit HTML 30K
55: EX-99.54 Miscellaneous Exhibit HTML 26K
56: EX-99.55 Miscellaneous Exhibit HTML 27K
57: EX-99.56 Miscellaneous Exhibit HTML 24K
58: EX-99.57 Miscellaneous Exhibit HTML 23K
59: EX-99.58 Miscellaneous Exhibit HTML 55K
60: EX-99.59 Miscellaneous Exhibit HTML 25K
7: EX-99.6 Miscellaneous Exhibit HTML 24K
61: EX-99.60 Miscellaneous Exhibit HTML 31K
62: EX-99.61 Miscellaneous Exhibit HTML 26K
63: EX-99.62 Miscellaneous Exhibit HTML 25K
64: EX-99.63 Miscellaneous Exhibit HTML 25K
65: EX-99.64 Miscellaneous Exhibit HTML 57K
66: EX-99.65 Miscellaneous Exhibit HTML 46K
67: EX-99.66 Miscellaneous Exhibit HTML 26K
68: EX-99.67 Miscellaneous Exhibit HTML 26K
69: EX-99.68 Miscellaneous Exhibit HTML 26K
70: EX-99.69 Miscellaneous Exhibit HTML 26K
8: EX-99.7 Miscellaneous Exhibit HTML 26K
71: EX-99.70 Miscellaneous Exhibit HTML 26K
72: EX-99.71 Miscellaneous Exhibit HTML 26K
73: EX-99.72 Miscellaneous Exhibit HTML 26K
74: EX-99.73 Miscellaneous Exhibit HTML 29K
75: EX-99.74 Miscellaneous Exhibit HTML 24K
76: EX-99.75 Miscellaneous Exhibit HTML 24K
77: EX-99.76 Miscellaneous Exhibit HTML 20K
78: EX-99.77 Miscellaneous Exhibit HTML 26K
79: EX-99.78 Miscellaneous Exhibit HTML 36K
80: EX-99.79 Miscellaneous Exhibit HTML 27K
9: EX-99.8 Miscellaneous Exhibit HTML 26K
81: EX-99.80 Miscellaneous Exhibit HTML 31K
82: EX-99.81 Miscellaneous Exhibit HTML 31K
83: EX-99.82 Miscellaneous Exhibit HTML 22K
84: EX-99.83 Miscellaneous Exhibit HTML 23K
85: EX-99.84 Miscellaneous Exhibit HTML 22K
86: EX-99.85 Miscellaneous Exhibit HTML 25K
10: EX-99.9 Miscellaneous Exhibit HTML 26K
| Prepared by R.R. Donnelley Financial -- EX-99.62 |
Exhibit 99.62
NEWS RELEASE
Aurinia To Present At The 34th Annual Cowen Health Care Conference
Victoria, BC, February 25, 2014 – Aurinia Pharmaceuticals Inc. (TSX-V:AUP) (“Aurinia” or the “Company”) today announced that Stephen Zaruby, its President and CEO, will present an overview of the Company and an update on the development of its lead drug candidate, voclosporin, as a therapy for lupus nephritis at the 34th Annual Cowen Health Care Conference on Monday, March 3 at 3:30 p.m. Eastern Time. The conference will be held at the Boston Marriott Copley Place Hotel.
Mr. Zaruby’s presentation will be webcast live and archived for at least 90 days on the Company’s website at www.auriniapharma.com under the “Presentations” tab in the Investors section.
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. Its lead drug, voclosporin, is a novel calcineurin inhibitor. Many members of Aurinia’s current leadership team are former senior managers of Aspreva Pharmaceuticals (“Aspreva”), which Galenica acquired for C$915 million in 2008. While at Aspreva, this management team executed one of the largest and most important lupus nephritis studies ever conducted, called the Aspreva Lupus Management Study (“ALMS”), which resulted in the emergence of mycophenolate mofetil as a new standard treatment for patients suffering from this devastating and potentially fatal disease. Aurinia holds global rights to all indications for voclosporin and has development and commercialization partners in Canada, Israel, South Africa and Greater China. Aurinia also holds certain rights to exploit the ALMS database. More information is available at www.auriniapharma.com.
Forward-looking Statements
This press release contains forward-looking statements. The forward-looking statements may include, without limitation, statements regarding the ability of the company to conduct clinical trials and to obtain the necessary regulatory approvals for its products.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the ability of the Company to protect its intellectual property rights, securing and maintaining corporate alliances and partnerships, the need to raise additional capital and the effect of capital market conditions and other factors on capital availability, the potential of its products, the success and timely completion of clinical studies and trials, and the combined company’s and its partners’ ability to successfully obtain regulatory approvals and commercialize voclosporin on a timely basis. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company’s ongoing quarterly filings, annual reports and the Annual Information Form and other filings found on SEDAR at www.sedar.com.
We seek Safe Harbour.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Company Contact:
Stephen W. Zaruby
President & CEO
250-708-4293
Investor & Media Contact:
Stephen Kilmer
647-872-4849
| This ‘40FR12B/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 6/19/14 | None on these Dates | ||
| Filed on: | 6/18/14 | |||
| 2/25/14 | ||||
| List all Filings | ||||